Thus, targeting GM-CSF and its signaling pathways could be a promising therapeutic approach, enabling strategies directed at mobilization, migration, and differentiation of circulating Ly6Chi monocytes to manage MS disease progression and symptom mitigation. This evidence concerns the gene CSF2 and myeloid sarcoma.